CDT CDT Equity Inc.

CIK 0001896212 50 ready 8-Ks latest August 21, 2026, 9:27 AM ET RSS · JSON

Activity: ELEVATED 4 filings / 30d vs 2 baseline

Ready 8-Ks 50

Latest filing August 21, 2026, 9:27 AM ET

Top materiality 0.85

Event mix other_material ×23 · debt ×8 · other ×8

Sentiment 6 pos · 13 neg · 31 neu

Executive change recent →

SHENANIGAN SCORE 3 / 7 see the board

Recent 8-K filings for CDT

Highest-materiality recent filing

Nasdaq notifies Conduit of delisting due to low price; shareholders approve reverse stock split

December 20, 2024, 6:59 PM ET regulatory materiality 0.85 negative item 3.01 item 5.02 item 5.07 ◈ Listing & Compliance Notices

Closing bid price ≤ $0.10 for 10 consecutive days; delisting set for Dec 27 unless hearing requested.
Company intends to request a hearing before Nasdaq Hearings Panel; delisting stayed pending decision.

Read filing →

August 21, 2026, 9:27 AM ET M&A materiality 0.70 neutral item 9.01

CDT Equity files Sarborg acquisition financials: FY25 revenue $4.6M, net loss $508K, going concern risk

Sarborg FY2025 revenue $4.626M vs $98K in 2024 (inception Oct 28, 2024); net loss $508K vs $282K.
August 21, 2026, 9:27 AM ET M&A materiality 0.65 neutral item 2.01 item 9.01 item 1.01 item 3.02

CDT Equity files amended 8-K for Sarborg investment; Sarborg 2025 revenue $4.6M, net loss $508K

Sarborg FY2025 revenue $4.6M, gross profit $4.2M, net loss $508K (vs. $98K revenue, $282K loss in 2024).
August 6, 2026, 4:30 PM ET debt materiality 0.75 negative item 1.01 item 2.03 item 3.02 item 9.01

CDT Equity amends convertible note, principal to $2.54M, 19% interest, issues warrants

Principal increased to $2,536,650 via second and third amendments; interest rate set at 19% per annum.
August 3, 2026, 4:15 PM ET other material materiality 0.10 neutral item 2.01 item 1.01 item 3.02 item 9.01

CDT Equity files amendment to 8-K for Sarborg Limited investments; financial statements deferred

Amendment No. 1 to original 8-K dated July 30, 2026, filed to include Items 2.01, 9.01(a), and 9.01(b) regarding Sarborg Limited investments.
July 31, 2026, 5:26 PM ET M&A materiality 0.80 neutral item 1.01 item 3.02 item 9.01

CDT Equity acquires 4.76% stake in Sarborg; issues pre-funded warrants for 12.1M shares

Acquired 270 shares of Sarborg (4.76% of outstanding) from investors in exchange for pre-funded warrants to purchase up to 12,131,770 shares of CDT common stock at $0.0001 per share.
July 29, 2026, 4:30 PM ET other materiality 0.20 neutral item 3.02

CDT Equity issues 32,110 shares at $3.27 for consulting services

Issued 32,110 shares of common stock at $3.27 per share to a service provider.
July 16, 2026, 8:05 AM ET other material materiality 0.60 negative item 3.03 item 5.03 item 7.01 item 9.01

CDT Equity announces 1-for-10 reverse stock split to comply with Nasdaq bid-price rule

Reverse stock split effective July 17, 2026 at 5:00 pm ET; trading on split-adjusted basis July 20, 2026.
July 7, 2026, 5:20 PM ET debt materiality 0.50 neutral item 1.01 item 2.03 item 9.01

CDT Equity amends loan agreement, closes second tranche of $1.46M convertible note

Amended Loan Agreement and Note executed June 30, 2026; second tranche of $1.46M loan funded.
June 29, 2026, 4:30 PM ET other materiality 0.75 negative item 4.01 item 9.01

CDT Equity dismisses auditor CBIZ CPAs, engages CRI; cites going concern, material weaknesses

Audit committee dismissed CBIZ CPAs and engaged Carr, Riggs & Ingram (CRI) on June 23, 2026.
June 16, 2026, 5:00 PM ET debt materiality 0.60 positive item 1.01 item 2.03 item 3.02 item 8.01 item 9.01 ◈ Material Agreements ×5◈ Debt Financings

CDT Equity repays $6.3M legacy debt, enters new $1.46M JJ Astor loan

Repaid $5,737,500 A.G.P. convertible loan notes and $555,556 Ascent Partners note, eliminating over $6.3M in legacy obligations.
May 28, 2026, 4:30 PM ET regulatory materiality 0.70 negative item 3.01 item 7.01 item 9.01 ◈ Listing & Compliance Notices

CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan

Received Nasdaq deficiency notice on May 21, 2026 for failing to timely file Q1 2026 Form 10-Q under Listing Rule 5250(c)(1).
May 15, 2026, 4:01 PM ET other material materiality 0.50 neutral item 1.01 item 9.01 ◈ Material Agreements

CDT Equity amends ELOC and convertible note; retains 90% of future proceeds, sets $510K purchase cap

Amendment No. 2 caps regular ELOC purchase at $510,000 without purchaser consent; extends adjustment period until all shares sold.
April 27, 2026, 7:59 PM ET other material materiality 0.50 neutral item 5.02

CDT Equity appoints Ulrik Olsen to board; Freda Lewis-Hall resigns

Freda Lewis-Hall resigned from board on April 27, 2026 for family health reasons; no disagreement with company.
March 25, 2026, 7:59 PM ET other material materiality 0.60 neutral item 3.03 item 5.03 item 7.01 item 9.01 ◈ Governance Changes

CDT Equity Inc. announces 1-for-25 reverse stock split effective March 26, 2026

Reverse stock split at 1:25 ratio; effective March 26, 2026 at 5:00 pm ET.
March 18, 2026, 7:59 PM ET other material materiality 0.70 neutral item 5.07

CDT Equity stockholders approve redomestication to Cayman Islands, reverse stock split, and share increase

Redomestication from Delaware to Cayman Islands approved (Proposal 6): ~2.22M for, 72K against, 21.9K abstain.
March 9, 2026, 7:59 PM ET debt materiality 0.60 neutral item 1.01 item 2.03 item 3.02 item 9.01 ◈ Material Agreements ×2◈ Debt Financings

CDT Equity lowers ELOC floor to $0.60 and issues $555K convertible note

Amendment cuts ELOC floor price to $0.60; max shares issuable ~41.7M, subject to stockholder approval.
February 24, 2026, 6:59 PM ET M&A materiality 0.75 neutral item 1.01 item 3.02 item 9.01 ◈ Equity Issuances ×5◈ Material Agreements ×3

CDT Equity acquires 20% of Sarborg for stock, warrants, deferred $8M cash

Acquired 1,020 Sarborg shares (~20% stake) in exchange for 598,006 shares + pre-funded warrants for 109,978,918 shares at $0.0001 exercise price.
January 22, 2026, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 9.01 ◈ Equity Issuances◈ Material Agreements

CDT Equity enters $25M equity line of credit with Ascent Partners; issues 204,031 commitment shares

CDT Equity entered a directed stock purchase agreement for up to $25M of common stock with institutional investor Ascent Partners.
January 2, 2026, 6:59 PM ET other material materiality 0.40 neutral item 1.01 item 3.02 item 7.01 item 9.01 ◈ Material Agreements ×2

CDT enters consulting pacts with Thesprogen and NJS; issues 213,288 shares for $305k in services

Thesprogen will evaluate AZD1656 pre-clinical data and optimize development strategies; 6-month term, $155k fee paid in 108,392 shares.
December 12, 2025, 6:59 PM ET M&A materiality 0.75 negative item 1.01 item 3.02 item 9.01 ◈ Equity Issuances ×2◈ Material Agreements

CDT sells CPL subsidiary to CEO affiliate Corvus for $7M to offload Strand litigation liability

CDT sells CPL to Corvus Capital (wholly-owned by CEO Andrew Regan) for $7M in common stock or pre-funded warrants.
October 9, 2025, 7:59 PM ET other materiality 0.50 neutral item 3.03 item 5.03 item 7.01 item 9.01 ◈ Governance Changes

CDT Equity announces 1-for-8 reverse stock split effective October 10, 2025

Reverse stock split of every 8 shares into 1, effective Oct 10, 2025 at 5:00 PM ET.
August 14, 2025, 7:59 PM ET other material materiality 0.65 negative item 4.02 ◈ Auditor Changes

CDT Equity restates Q1 2025 financials; $0.4M milestone misclassified as R&D

On Aug 8, 2025, CDT Equity determined its unaudited Q1 2025 financials should no longer be relied upon.
August 8, 2025, 7:59 PM ET other material materiality 0.65 neutral item 5.02 item 5.03 item 5.07 item 7.01 item 9.01 ◈ Governance Changes ×2

Conduit renames to CDT Equity Inc., appoints James Bligh permanent CFO, adds 2M shares to incentive plan

Name change from Conduit Pharmaceuticals Inc. to CDT Equity Inc. effective Aug 5, 2025; ticker remains CDT; no shareholder vote required.
June 9, 2025, 7:59 PM ET other material materiality 0.55 neutral item 1.01 item 3.02 item 7.01 item 9.01

Conduit enters joint development with Manoira for AZD1656/AZD5658 in animal health

Conduit grants Manoira non-exclusive license to AZD1656 and AZD5658 for veterinary use; Manoira funds development.
June 3, 2025, 7:59 PM ET other material materiality 0.25 neutral item 5.08

Conduit Pharmaceuticals sets 2025 annual meeting for Aug 5; proxy deadlines June 17

Annual meeting scheduled for August 5, 2025; record date is July 3, 2025.
May 16, 2025, 7:59 PM ET other material materiality 0.50 neutral item 3.03 item 5.03 item 7.01 item 9.01 ◈ Governance Changes

Conduit Pharmaceuticals announces 1-for-15 reverse stock split effective May 19, 2025

1-for-15 reverse split effective May 19, 2025 at 5:00 p.m. ET; split-adjusted trading begins May 20 under ticker CDT.
May 6, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.07

Conduit Pharma stockholders approve reverse stock split up to 1-for-250 at special meeting

Proposal passed with 5,065,868 votes for, 496,473 against, 1,438 abstentions.
April 25, 2025, 7:59 PM ET other material materiality 0.70 negative item 4.01 item 9.01 ◈ Auditor Changes ×2

Conduit Pharmaceuticals changes auditor from Marcum to CBIZ CPAs; going concern and material weaknesses cited

Marcum LLP resigned as independent auditor on April 24, 2025; CBIZ CPAs P.C. appointed on April 25, 2025.
April 16, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Conduit Pharma appoints founder Andrew Regan as CEO; Tapolczay transitions to licensing role

David Tapolczay resigned as CEO and board member effective April 12, 2025; to serve as Head of Licensing & Strategy at £240K salary.
April 4, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02

Conduit Pharmaceuticals enters AI analytics deal for AstraZeneca assets; issues 2.26M shares

Entered additional agreement with Sarborg for AI analysis of AZD1656, AZD5658, AZD5904 clinical data to identify repurposing opportunities.
April 2, 2025, 7:59 PM ET regulatory materiality 0.65 positive item 8.01

Conduit Pharmaceuticals regains full Nasdaq compliance after $8.3M raise and debt conversion

Submitted pro-forma financials showing stockholder's equity of $2.8M vs $2.5M minimum required.
April 1, 2025, 7:59 PM ET other materiality 0.65 positive item 8.01

Conduit Pharmaceuticals provides Nasdaq compliance update; equity above $2.5M threshold

Submitted pro-forma financials showing Stockholder's Equity of $2.8M as of March 31, 2025, above Nasdaq's $2.5M minimum.
March 6, 2025, 6:59 PM ET regulatory materiality 0.65 neutral item 8.01

Conduit Pharmaceuticals receives Nasdaq extension, plans transfer to Capital Market

Nasdaq Hearing Panel granted extension to March 31, 2025 to regain MVPHS and MVLS compliance.
February 19, 2025, 6:59 PM ET other material materiality 0.75 neutral item 1.02 item 8.01 item 3.01 ◈ Listing & Compliance Notices

Conduit Pharmaceuticals repays $926k note, receives Nasdaq delisting basis for continued listing deficiencies

Paid remaining $926,149 on Senior Note to Nirland Limited on Feb 13, 2025; all assets now free of liens.
February 11, 2025, 6:59 PM ET other material materiality 0.55 positive item 8.01

Conduit Pharmaceuticals repays $600K note; lender converts $1.7M Senior Note

Paid full principal of $600,000 promissory note on Feb 7, 2025; note bore 12% interest and matured Oct 31, 2025.
January 23, 2025, 6:59 PM ET other material materiality 0.60 neutral item 3.03 item 5.03 item 7.01 item 9.01 ◈ Governance Changes

Conduit Pharmaceuticals announces 1-for-100 reverse stock split to meet Nasdaq bid price requirement

Effective Jan 24, 2025 at 5pm ET; shares begin trading on split-adjusted basis Jan 27 under ticker CDT.
January 14, 2025, 6:59 PM ET other materiality 0.15 neutral item 5.07

Conduit shareholders approve issuance of up to 135.9M shares via warrant exercises and note conversions

Proposal 1: approved 2,862,596 shares from warrant exercise (38.1M for, 1.5M against).
December 20, 2024, 6:59 PM ET regulatory materiality 0.85 negative item 3.01 item 5.02 item 5.07 ◈ Listing & Compliance Notices

Nasdaq notifies Conduit of delisting due to low price; shareholders approve reverse stock split

Closing bid price ≤ $0.10 for 10 consecutive days; delisting set for Dec 27 unless hearing requested.
December 17, 2024, 6:59 PM ET other material materiality 0.55 positive item 1.01 item 3.02 item 7.01 item 9.01

Conduit signs AI services deal with Sarborg; upfront $400K, up to $1.8M milestones

Agreement with SARBORG for algorithmic AI/cybernetics services to optimize drug development, repurposing, and clinical trials.
November 25, 2024, 6:59 PM ET debt materiality 0.65 negative item 1.01 item 2.03 item 3.02 item 9.01

Conduit Pharma issues $5.74M convertible note to A.G.P. and amends Nirland note; conversion needs stockholder approval

Issued $5,737,500 convertible note to A.G.P. for deferred commission; 5.5% interest, matures Nov 25, 2025.
November 19, 2024, 6:59 PM ET leadership materiality 0.45 neutral item 5.02 item 5.03 item 9.01 ◈ executive_change◈ Governance Changes

Conduit Pharma appoints director Fry (420K options); amends CFO pay (£400K, 40% bonus) and quorum rule

Simon Fry appointed as director effective Dec 18, 2024; receives initial option for 420,000 common shares.
November 14, 2024, 6:59 PM ET other material materiality 0.40 negative item 4.02 ◈ Auditor Changes

Conduit Pharmaceuticals restates Q1 and Q2 2024 financials; reclassifies deferred commission to current liability

Previously issued unaudited financials for Q1 and Q2 2024 should no longer be relied upon due to reclassification error.
November 1, 2024, 7:59 PM ET debt materiality 0.65 negative item 1.01 item 1.02 item 2.03 item 3.02 item 9.01

Conduit Pharmaceuticals secures $1.2M in new loans; issues warrants and amends existing debt

Entered Bridge Loan with A.G.P. for up to $600k at 4.21% due Dec 31, 2024; issued warrants for 2.86M shares at $0.1048 per share, subject to shareholder approval.
October 15, 2024, 7:59 PM ET debt materiality 0.55 negative item 1.01 item 2.03 item 9.01

Conduit extends $800K convertible note, issues 2.78M shares

Original $800K convertible note (20% interest) due Sept 20, 2024 amended; maturity extended to Oct 20, 2024, with possible further 30-day extensions.
September 6, 2024, 7:59 PM ET other materiality 0.30 neutral item 5.08

Conduit Pharmaceuticals postpones 2024 Annual Meeting to Dec 18, sets deadlines

Annual Meeting postponed from Oct 2 to Dec 18, 2024.
August 16, 2024, 7:59 PM ET other material materiality 0.85 negative item 3.01 item 8.01

Conduit Pharmaceuticals receives Nasdaq delisting notices; discloses 31% of shares pledged without company knowledge

Nasdaq notified Conduit on Aug 15, 2024 for non-compliance: MVPHS <$15M and MVLS <$50M; 180-day cure period until Feb 11, 2025.
August 8, 2024, 7:59 PM ET other material materiality 0.80 positive item 1.01 item 3.02 item 9.01

Conduit licenses three AstraZeneca assets for autoimmune and infertility; issues 9.5M shares

Exclusive license from AstraZeneca for HK-4 glucokinase activators AZD1656, AZD5658 and MPO inhibitor AZD5904.
August 7, 2024, 7:59 PM ET debt materiality 0.65 neutral item 1.01 item 2.03 item 3.02 item 9.01

Conduit Pharmaceuticals issues $2.65M secured note at 12%, 12.5M shares to Nirland

Senior Secured Promissory Note of $2,650,000 (incl. $500,000 OID), 12% interest, matures Aug 5, 2025.
July 11, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.08

Conduit Pharmaceuticals announces Oct 2, 2024 annual meeting; record date Aug 12, 2024

Annual meeting set for October 2, 2024; record date for stockholders is August 12, 2024.
July 1, 2024, 7:59 PM ET other materiality 0.25 neutral item 5.08

Conduit Pharmaceuticals sets 2024 annual meeting for Oct 2; deadline for shareholder proposals July 11

Annual Meeting date: October 2, 2024; record date: August 20, 2024.

Executive changes

Appointed

Andrew Regan

Chief Executive Officer

CDT · CDT Equity Inc.

Effective: 2025-04-15
Filed: April 16, 2025, 7:59 PM ET

Appointed

Simon Fry

director

CDT · CDT Equity Inc.

Effective: 2024-12-18
Filed: November 19, 2024, 6:59 PM ET

Appointed

Faith L. Charles

Director

CDT · CDT Equity Inc.

Effective: 2023-09-22
Filed: October 5, 2023, 7:59 PM ET

Appointed

Freda Lewis-Hall

Director

CDT · CDT Equity Inc.

Effective: 2023-09-22
Filed: October 5, 2023, 7:59 PM ET

Appointed

David Tapolczay

Chief Executive Officer

CDT · CDT Equity Inc.

Effective: 2023-09-22
Filed: October 5, 2023, 7:59 PM ET

Appointed

Jennifer I. McNealey

Director

CDT · CDT Equity Inc.

Effective: 2023-09-22
Filed: October 5, 2023, 7:59 PM ET

Appointed

James Bligh

Director

CDT · CDT Equity Inc.

Effective: 2023-09-22
Filed: October 5, 2023, 7:59 PM ET

Appointed

Freda Lewis-Hall

Chair of the Board

CDT · CDT Equity Inc.

Effective: 2023-09-22
Filed: October 5, 2023, 7:59 PM ET

Appointed

Andrew Regan

Director

CDT · CDT Equity Inc.

Effective: 2023-09-22
Filed: October 5, 2023, 7:59 PM ET

Appointed

David Tapolczay

Director

CDT · CDT Equity Inc.

Effective: 2023-09-22
Filed: October 5, 2023, 7:59 PM ET

Appointed

David Tapolczay

Director

CDT · CDT Equity Inc.

Effective: 2023-09-22
Filed: September 29, 2023, 7:59 PM ET

Appointed

Faith L. Charles

Director

CDT · CDT Equity Inc.

Effective: 2023-09-22
Filed: September 29, 2023, 7:59 PM ET

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

6 positive 13 negative 31 neutral

source · CDT on sec.gov